DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Clinical trials for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS trials appear
Sign up with your email to follow new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising drug for rare Skin-Hardening disease fails to complete trial
Disease control TerminatedThis study tested a drug called HZN-825 in about 300 people with diffuse cutaneous systemic sclerosis, a rare condition that causes skin thickening and can affect the lungs. Participants took either a low dose, a high dose, or a placebo for 52 weeks. The trial was stopped early, …
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated May 26, 2026 04:57 UTC
-
Promising drug trial for rare skin disease halted early
Disease control TerminatedThis study tested a drug called HZN-825 in people with diffuse cutaneous systemic sclerosis, a rare disease that causes skin thickening and can harm internal organs. The goal was to see if the drug could improve lung function and was safe over 52 weeks. The trial was terminated e…
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated May 26, 2026 04:38 UTC